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Abstract
Background: Genome-wide association studies (GWASs) have identified several single-nucleotide polymorphisms
(SNPs) influencing the risk of thyroid cancer (TC). Most cancer predisposition genes identified through GWASs
function in a co-dominant manner, and studies have not found evidence for recessively functioning disease loci in
TC. Our study examines whether homozygosity is associated with an increased risk of TC and searches for novel
recessively acting disease loci.
Methods: Data from a previously conducted GWAS were used for the estimation of the proportion of phenotypic
variance explained by all common SNPs, the detection of runs of homozygosity (ROH) and the determination of
inbreeding to unravel their influence on TC.
Results: Inbreeding coefficients were significantly higher among cases than controls. Association on a SNP-by-SNP
basis was controlled by using the false discovery rate at a level of q* < 0.05, with 34 SNPs representing true
differences in homozygosity between cases and controls. The average size, the number and total length of ROHs
per person were significantly higher in cases than in controls. A total of 16 recurrent ROHs of rather short length
were identified although their association with TC risk was not significant at a genome-wide level. Several recurrent
ROHs harbor genes associated with risk of TC. All of the ROHs showed significant evidence for natural selection
(iHS, Fst, Fay and Wu’s H).
Conclusions: Our results support the existence of recessive alleles in TC susceptibility. Although regions of
homozygosity were rather small, it might be possible that variants within these ROHs affect TC risk and may
function in a recessive manner.
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Background
Thyroid cancer (TC) is the most common malignancy of
the endocrine system with incidence rates being 2 to 3
times higher in women compared with men [1, 2]. In
economically developed countries, 0.5 to 10 TC cases
are diagnosed per 100 000 individuals each year [1].
Significant regional differences are seen in Europe with
Italy being among the countries with the highest inci-
dence rates in the world (Cancer Incidence in Five
Continents, IX, 2000, http://www.iarc.fr/en/publications/
pdfs-online/epi/sp160/). While exposure to ionizing radi-
ation or insufficient iodine intake is an established risk fac-
tor, anthropometric risk factors such as high body surface
area, great height, or excess weight have been associated
with increased TC risk [3]. However, TC is also character-
ized by having one of the highest familial risks of any can-
cer supporting heritable predisposition [4–6]. A high risk
of TC is associated with some genetic disorders, but most
of the familial risk of TC remains unexplained [7]. During
the last years genome-wide association studies (GWASs)
have provided robust evidence for common susceptibility
to TC. At least four GWASs have identified a set of genes
with susceptibility for TC [8–11]. These studies suggest
that much of the familial risk of TC may be due to the
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coinheritance of multiple low/moderate-penetrant alleles,
some of which may be common. The majority of cancer
predisposition genes identified through the GWASs
function in a co-dominant manner, and no evidence
has been found for recessively functioning disease loci
in TC, although the risk for TC among siblings is
much higher than the parent-offspring risk, suggesting
recessive inheritance [6]. Recessive inheritance has
been associated with consanguinity or an increased
risk in populations characterized by a higher degree
of inbreeding and corresponding homozygosity [12].
A consecutive pattern, called runs of homozygosity
(ROH), appears mainly in an increased frequency due
to a high level of relatedness between individuals within a
population or due to selection [13]. These ROHs are
shown to predispose to many genetic diseases includ-
ing cancers [14–16]. The siblings-risk and the fact
and that TC is part of recessively inherited syndromes
such as the Werner syndrome make TC an ideal tar-
get to search for recessively acting disease loci [6, 7].
In a first step we estimated the proportion of the total
phenotypic variance explained by all common SNPs for
TC risk. This was followed by a whole-genome homozy-
gosity analysis based on our previous GWAS in the
high-incidence Italian population. The aim of our study
was to examine whether inbreeding or homozygosity is
associated with an increased risk of TC and to search for
novel recessively acting disease loci.
Methods
Ethics statement
Study participants were recruited according to the
protocols approved by the institutional review boards in
accordance with the Declaration of Helsinki. All subjects
provided written informed consent. This study was
approved by the ethics committees of the University
Hospitals of Cisanello and Santa Chiara in Pisa, Italy and
of the Meyer Hospital in Florence, Italy.
Genomic data - quality control of SNP genotyping
The study is based on the genotyping data of our previ-
ously performed GWAS on the Italian cases and con-
trols, and did not include any new participants [11, 17].
All patients were ascertained with papillary thyroid can-
cer (PTC) through the University Hospital Cisanello in
Pisa. After a stringent quality control procedure the final
set consisted of 649 cases and 431 controls with geno-
type data on 536 270 SNPs [18, 19]. Data have been sub-
mitted to a central database: www.gwascentral.org.
Proportion of the total phenotypic variance explained by
all common SNPs
The approach of Yang et al. was used to estimate the
proportion of the total phenotypic variance explained by
all common SNPs [20]. First, we estimated the genetic
relationship matrix (GRM) for each individual autosome
of all the individuals and fitted the GRMs in a mixed lin-
ear model (MLM) to estimate the proportion of the
phenotypic variance explained by all common SNPs. We
repeated this scenario after excluding 15 identified
GWAS regions for TC including the genomic region
500 kb upstream and downstream [11, 17]. This left us
with a total of 520 137 autosomal SNPs.
For both scenarios sex and eigenvectors from 10
principal components of the population structure
were used as covariates. Consecutive estimates on the
observed 0–1 scale are linearly transformed to that
on the unobserved continuous liability scale such that
hl
2 = h0
2K(1 − K)/z2 [21], where K is the prevalence of
the disease and z is the value of the standard normal
probability density function at the threshold t. Given
an incidence of 8 – 9/100 000/year will result in a
cumulative risk of ~ 6 in 1000 as an estimate of the
prevalence. Estimation was performed using restricted
maximum likelihood (REML) via the genome-wide
complex trait analysis (GCTA) software [22].
Genome-wide assessment of associations between
homozygosity at individual SNPs and TC
A chi2-test was performed to test for any association
between homozygosity and susceptibility of TC on a
SNP-by-SNP basis in our entire sample series [14]. To
control the problem of multiple testing the false discov-
ery rate (FDR) was calculated and controlled at an arbi-
trary level q* < 0.05 [23].
Statistical and bioinformatics analysis
We defined ROHs following recommendations in How-
rigan et al. [24] ROHs were detected using PLINK
(v1.07) software. To prevent overestimating the number
and size of ROHs no heterozygous SNPs were permitted
in any window. We kept the remaining options to de-
fault values. The parameter for the “homozyg-kb” option
was also kept at the default value of 1000 kb to select in-
dividual segments of minimal length. We only varied the
parameter “homozyg-snp” option according to the defin-
ition of ROHs as below. Subsequent statistical analyses
were performed using packages available in the R statis-
tics package [25]. Comparison of the distribution of cat-
egorical variables was performed using the chi2-test. To
compare the difference in the average number of ROHs
between cases and controls, we used the Student’s t-test.
Naive adjustment for multiple testing was based on the
Bonferroni correction.
Identification of homozygosity
We used the method of Lencz et al. to estimate the
minimum number of consecutive homozygous SNPs
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required to form a ROH that was more than an order of
magnitude larger than the mean haploblock size in the
human genome without being too large to be very rare
[26]. In our TC data, with 1080 individuals and 536 270
SNPs, the mean heterozygosity in controls was calcu-
lated to be 35 %. Thus, a minimum length of 53 would
be required to produce <5 % randomly generated ROHs
across all subjects: ((1–0.35)53 × 536 270 × 1080 ≤ 0.05).
Due to linkage disequilibrium (LD) between the SNPs,
the SNP genotypes are not always independent. Pairwise
LD was estimated using the SNP pruning function of
PLINK, with a default value of r2 > 0.8 and restricting
the search of tagging SNPs within each 250 kb window.
Approximately 377 000 separable tag groups were
Table 1 Association between homozygosity and susceptibility to TC for individual SNPs
SNP CHR BPa Cases AA/BB Cases AB Controls AA/BB Controls AB chi2 Pb q*c Genes
rs4698482 4 16020011 519 116 274 157 44.43 2.62 × 10−11 1.40 × 10−5 LDB2
rs11688848 2 204624451 512 119 275 156 40.10 2.40 × 10−10 5.38 × 10−5 ICOS
rs9578483 13 22068754 543 97 296 135 39.66 3.01 × 10−10 5.38 × 10−5 FGF9, FTHL7
rs839509 2 212530542 497 126 270 160 37.09 1.12 × 10−9 0.0001 ERBB4, CPS1,
hCG_1645016
rs2414003 15 48105489 514 122 280 151 33.90 5.77 × 10−9 0.0006 ATP8B4, SLC27A2
rs3096381 16 69875502 525 116 289 141 30.46 3.39 × 10−8 0.0028 FLJ11171, HYDIN, CALB2
rs630695 6 117359452 526 103 299 132 30.10 4.09 × 10−8 0.0028 RFXDC1, GPRC6A, VGLL2
rs938845 18 63860975 512 122 284 147 30.02 4.26 × 10−8 0.0028 NA
rs17797954 5 174303096 516 122 287 144 28.09 1.15 × 10−7 0.0068 DRD1
rs10961997 9 15361675 509 134 279 152 27.48 1.58 × 10−7 0.0083 SNAPC3
rs12126497 1 166939482 586 56 346 85 27.33 1.71 × 10−7 0.0083 DPT, XCL1
rs509716 6 131475408 532 113 297 134 26.90 2.13 × 10−7 0.0095 EPB41L2, AKAP7
rs6715968 2 229884476 484 141 272 159 25.75 3.86 × 10−7 0.0159 PID1, DNER
rs712082 1 222792683 545 98 311 120 25.32 4.83 × 10−7 0.0173 WDR26, AKR1B1P1
rs6440553 3 149713261 545 84 321 110 25.32 4.84 × 10−7 0.0173 RPL38P1
rs8043171 15 90065471 529 105 304 127 25.07 5.50 × 10−7 0.0184 SLCO3A1
rs12902263 15 69429108 556 87 321 110 24.77 6.44 × 10−7 0.0197 THSD4, hCG_2004593,
NR2E3
rs10254361 7 119351441 522 116 296 135 24.72 6.62 × 10−7 0.0197 KCND2
rs11563992 7 27347461 507 115 294 136 24.16 8.86 × 10−7 0.0242 NA
rs7018634 9 20249528 538 100 310 121 24.11 9.05 × 10−7 0.0242 SLC24A2, SMNP
rs11169076 12 48261675 571 72 335 96 23.99 9.68 × 10−7 0.0247 MCRS1, FAM186B
rs1943939 18 69856260 556 62 342 89 23.22 1.43 × 10−6 0.0332 FBXO15,
rs12660310 6 167051901 503 120 292 139 23.18 1.46 × 10−6 0.0332 RPS6KA2, RNASET2
rs11204947 1 150484881 489 135 280 151 23.16 1.48 × 10−6 0.0332 HRNR, FLG,
rs3821310 2 74923771 581 61 345 85 23.06 1.56 × 10−6 0.0335 HK2, SEMA4F, POLE4
rs9407406 9 8229748 532 95 314 117 22.93 1.67 × 10−6 0.0345 C9orf123, PTPRD
rs2830028 21 26349119 493 133 282 148 22.64 1.94 × 10−6 0.0386 APP, GABPA, CYYR1
rs11151652 18 67133203 554 91 319 110 22.52 2.07 × 10−6 0.0397 CBLN2
rs10779770 1 12529312 537 97 314 117 22.42 2.18 × 10−6 0.0403 VPS13D, DHRS3
rs1508833 5 38050010 519 108 303 127 22.35 2.26 × 10−6 0.0404 GDNF, EGFLAM
rs554232 8 102533760 540 98 314 117 22.23 2.40 × 10−6 0.0408 NACAP1, GRHL2
rs2102727 8 53063166 502 133 285 146 22.21 2.43 × 10−6 0.0408 PCMTD1, ST18,
rs9379246 6 8777273 571 67 341 90 22.11 2.56 × 10−6 0.0416 HULC
rs7481683 11 8157762 454 174 252 179 21.98 2.75 × 10−6 0.0434 RIC3, LMO1
aGenome build hg18
bP was calculated using a simple 2x2 chi2 test based on the number of homozygotes and heterozygotes at each SNP in cases and controls
cq *values representing the false discovery rate (FDR)
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discovered, representing an >25 % reduction of informa-
tion compared with the original number of SNPs. Thus,
ROH length of 75 was used to approximate the degrees
of freedom of 53 independent SNP calls.
The R statistics package was used to identify a list
of ‘common’ ROHs with 75 consecutive homozygous
SNP calls across a certain number of samples and
with each ROH having identical start and end loca-
tions across the individuals. The “homozyg-group” op-
tion of the PLINK package was used to produce a file
of the overlapping ROHs separated into pools con-
taining the number of cases and controls carrying the
ROH. We considered pools with more than five sam-
ples and at least 500 kb of length as recurrent ROHs.
A consensus SNP set representing the minimal over-
lapping region across all samples in the pool was
used to define the recurrent ROHs. The association
of the recurrent ROHs was then tested for differences
of the average proportion of ROHs among cases and
controls. Within each overlapping ROH the propor-
tion of homozygous genotypes at each SNP was
calculated for cases and controls separately, and the
significance of the difference was tested by a one-
tailed t-test.
Testing the effects of natural selection
We used three metrics, the integrated haplotype score
(iHS), the fixation index (Fst) and Fay and Wu’s H to inves-
tigate the selective pressure due to demographic events
(e.g. bottleneck events, founder effects or population isola-
tion) on each recurrent ROH [27, 28]. All metrics were
obtained from Haplotter Software (University of Chicago,
Chicago, IL, USA; http://haplotter.uchicago.edu/) [28, 29].
Testing the effects of inbreeding
To test whether inbreeding influenced the susceptibil-
ity to TC, three different inbreeding coefficients (F I,
F II and F III) were derived for each individual based
on their SNP data using GCTA [22]. The coefficients
were tested for differences between cases and controls
using a Student’s t-test. We also used a generalized
linear regression model (GLM) and regressed F I, F II
or F III as explanatory variables on the disease status
of the TC patient as the binary response (0/1). We
included several covariates in the model: the sex of
the individuals, the first 10 ancestry-informative prin-
cipal components and the percentage of SNPs missing
for an individual.
A genomic measure of individual homozygosity
(FROH) was calculated by a method proposed by
McQuillan et al. [30] in which LROH is the sum of
ROHs per individual above a certain criterion length (i.e.
1000 kb as defined beforehand) and LAUTO is the total
SNP-mappable autosomal genome length, excluding the
centromeres:
FROH ¼
X
LROH= LAUTO
The estimate of the total genome captured was 2 677 608
286 bp. FROH estimates inbreeding differently compared to
the coefficients based on SNP-by-SNP indices F I, F II and
F III as it considers only homozygous regions above a pre-
defined length criterion (i.e. 1000 kb). Due to the FROH dis-
tribution in our sample we divided ROHs into two classes,
below and above 1500 kb, and FROH was calculated overall,
and for the two subclasses using the R statistics package
[25]. The overall FROH was also tested for differences be-
tween cases and controls using a Student’s t-test.
Results
After stringent quality control and exclusion of ex-
treme population outliers the overall genetic matching
was satisfying with a genomic control inflation factor
at λgc = 1.00 within the prior GWAS, indicating that
no population stratification was present [11].
Proportion of total phenotypic variance explained by SNPs
The proportion of the total phenotypic variance ex-
plained by SNPs from the joint analysis transformed
to the liability scale after Dempster and Lerner
showed a value of 0.51 (SE 0.16 at P ≤ 1.97 × 10−7)
[21]. After the exclusion of the regions covered by
the previously identified TC risk SNPs the proportion
of the total phenotypic variance explained by the so
far unidentified SNPs was 0.33 (SE 0.15 at P ≤ 0.003).
While most of variance explained by common SNPs
for individual autosomes stayed constant, a major
drop was detected for chromosome 2 encompassing
Table 2 Association between overall ROH and TC (min. 75 SNPs
per ROH)
Entire data set
Number of ROHa Cases Controls OR 95 % CI P
< 10 204 152 1.00 Ref.
10–12 145 88 1.22 0.87–1.72 0.23
13–15 170 127 0.99 0.73–1.36 0.98
> 15 130 64 1.55 1.05–2.18 0.02
Total length (Mb)
< 14.1 153 117 1.00 Ref.
14.1–19.4 156 114 1.04 0.74–1.47 0.79
19.4–25.4 163 107 1.16 0.82–1.64 0.38
> 25.4 177 93 1.45 1.02–2.06 0.03
aCutoffs were chosen to produce approximately equal group sizes for cases
and controls
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DIRC3 (from 0.11 to 0.03) and for chromosome 9
encompassing FOXE1 (from 0.17 to 0.08).
Genome-wide assessment of associations between
homozygosity at individual SNPs and susceptibility to TC
Results of the association between homozygosity and the
susceptibility to TC on a SNP-by-SNP basis are shown
in Table 1. The FDR was calculated and controlled at an
arbitrary level q* < 0.05, for which 34 SNP were signifi-
cant [23]. Corresponding odds ratios (ORs) of the one-
sided Fisher’s exact test to prove the hypothesis that in-
creased homozygosity is associated with higher risk of
TC showed a minimum of OR = 1.85 with a 95 % confi-
dence interval of 1.23–3.41 for all SNPs in Table 1.
Table 3 List of ROHs associated with TC
ROH Chr. Start – End (bp)a Cases/controls Chi2 Pb Pc iHS maxd Fst max
e Fay and Wu’s Hf Genesg
ROH1 2 167204846–167895993 6 / 15 8,87 0.002 1.44 × 10−4 3.50 0.50 −74.64 XIRP2
ROH2 3 121016843–121689105 10 / 0 6,70 0.009 9.43 × 10−6 2.76 0.50 −37.03 GSK3B, FSTL1, LRRC58,
GPR156
ROH3 10 44969326–45928700 5 / 11 5,63 0.01 6.12 × 10−5 1.85 0.35 −57.08 ALOX5, OR13A1, ANUBL1,
CTGLF1, MARCH8, OR6D1P,
FAM21C, CTGLF10P
ROH4 6 69734043–70381283 2 / 7 5,42 0.01 0.007 2.58 0.27 −31.48 BAI3g
ROH5 9 73966521–74829925 2 / 7 5,42 0.01 1.60 × 10−12 2.05 0.44 −19.76 ALDH1A1, ZFAND5, TMC1
ROH6 1 217208583–218034929 7 / 0 4,67 0.03 0.08 2.17 0.41 −55.42 LYPLAL1, ZC3H11B
ROH7 2 26036646–26765583 7 / 0 4,67 0.03 0.18 2.42 0.61 −64.28 HADHA, HADHB, OTOF,
RAB10, SELI, C2orf39,
CIB4, FAM59B, PPIL1P1,
GPR113, C2orf70
ROH8 2 75174688–76481471 7 / 0 4,67 0.03 0.03 2.78 0.57 −66.54 C2orf3, MRPL19, FAM176A,
ROH9 1 177243354–178385972 6 / 0 4,00 0.04 1.67 × 10−4 2.67 0.38 −56.96 ABL2, SOAT1, NPHS2,
CEP350, FAM20B,
TOR1AIP1, IFRG15,
TOR3A, C1orf125,
FAM163A, TDRD5,
TOR1AIP2
ROH10 2 112182736–113192306 6 / 0 4,00 0.04 0.02 2.54 0.41 −24.47 SLC20A1, MERTK, ANAPC1,
POLR1B, CHCHD5, ZC3H8,
TMEM87B, FBLN7, TTL,
ZC3H6, RGPD8,
ROH11 2 113858688–114678121 6 / 0 4,00 0.04 0.83 2.37 0.50 −48.23 ACTR3, RABL2A, SLC35F5,
RPL23AP7, CBWD2,
RP11-395 L14.12,
FOXD4L1, WASH2P
ROH12 4 181001922–181547116 6/ 0 4,00 0.04 0.33 2.29 0.53 −36.74 NA
ROH13 4 182307562–182564832 6 / 0 4,00 0.04 0.35 2.09 0.30 −31.12 hCG_2025798
ROH14 4 183848547–184539543 6 / 0 4,00 0.04 1.00 × 10−8 2.09 0.65 −56.96 DCTD, CLDN22, WWC2,
C4orf38, FAM92A3,
CLDN24
ROH15 9 107008151–108187183 6 / 0 4,00 0.04 0.51 2.75 0.58 −46.35 FKTN, TAL2, SLC44A1,
GARNL2P, TMEM38B,
FSD1L, DEPDC1P2
ROH16 15 96502627–98965249 6 / 0 4,00 0.04 3.01 × 10−12 3.09 0.65 −110.70 IGF1R, MEF2A, HSP90B2P,
SYNM, LINS1, TTC23,
LRRC28, LYSMD4,
ADAMTS17, C15orf51,
LASS3, FAM169B,
FLJ42289, PRKXP1
aChromosomal positions derived from the National Center for Biotechnology Information (NCBI), build 36, hg18
bSuggestive significance
cSignificances for testing differences in homozygosity with H0 : μCases = μControls; H1 : μCases > μControls;
dRepresents maximal absolute values for iHS, derived for CEU population ancestry from Haplotter, Phase II (http://haplotter.uchicago.edu/)
eRepresents maximal values for Fst, derived for CEU population ancestry from Haplotter, Phase II
fRepresents minimum values for Fay and Wu’s H, derived for CEU population ancestry from Haplotter, Phase II
gin flanking region
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Identification of ROHs and association between ROHs and
TC susceptibility
We identified a total of 12 306 individual ROHs greater
than 1000 kb across all 1080 individuals with 7523
ROHs in cases and 4783 ROHs in controls. On average
11.39 ROH segments with a total overall length of 22
980 kb per individual were detected. The average num-
ber of ROH segments per person in cases was 11.59 and
in controls 11.09 (Pdiff = 4.00 × 10
−2), the total length of
ROHs per person was 4761 kb higher in cases than in
controls (Pdiff = 1.95 × 10
−5), and the average ROH length
per person in kb was significantly higher in cases
(1988 kb) than in controls (1788 kb) (Pdiff = 3.29 × 10
−8).
We extended the tests for association between ROHs
and susceptibility to TC by categorizing the number of
ROHs and the total length of ROHs in Mb by forming
control groups of similar size. They were compared with
the numbers of cases within the corresponding classes
(Table 2). Cases had more ROHs and the total length of
ROHs was also longer than in controls. (e.g. for entire
data set >15 ROHs, OR = 1.55, P = 0.02; for >25.4 Mb,
OR = 1.45, P = 0.03).
For further association analysis 2262 consensus
groups were formed, of which a total of 225 ROHs
were identified, that fulfilled the criteria of identical
start and end location and at least 75 consecutive
homozygous SNPs [26]. An example for an overlap-
ping region is given in the Additional file 1: Figure S1.
None of the ROHs were associated with susceptibility to
TC after correction for multiple testing. However, 16
ROHs were associated at a suggestive level (P < =0.05)
(Table 3). None of them encompassed the centromeric
regions.
Intriguingly, several recurrent ROHs harbor genes
that have been associated with risk or progression
of TC (Table 3). The first consensus region, located
on chromosome 2, shows the strongest association
with TC susceptibility (uncorrected P value = 0.002,
ROH1 in Table 3). Six cases and 15 controls carried
a ROH spanning this region of 79 homozygous
SNPs. Another consensus region on chromosome 3
(ROH2) spans 672 kb and contains 98 SNPs. Genes
and predicted transcripts include GSK3B, FSTL1,
LRRC58, GPR156. A consensus region on chromo-
some 10 spanning 81 SNPs on a length of 959 kb
(ROH3, P = 0.01) also hosts a considerable number
of genes.
To scrutinize the significant ROH consensus regions,
the average homozygosity for all SNP loci within a cor-
responding ROH was computed for cases and controls
separately and tested for a difference with a one-tailed
Student’s t-test (Table 3, column 9). Ten ROHs showed
significant differences at P < 0.05 level, of which 6 had
more cases than controls.
Natural selection as a cause of ROHs
To assess the influence of selection on the recurrent
ROH regions, we used the measures iHS, Fst and Fay
and Wu’s H [28, 29, 31, 32]. Every recurrent ROH
showed significant values for the three estimates (iHS
>2.0, Fst >0.2 and Fay and Wu’s H < <−10; Table 3), ex-
cept for ROH3, for which the iHS value was 1.85. This
indicates that each of the 16 ROH regions might be the
result of a selective sweep.
Inbreeding and association between homozygosity
and TC
We formally calculated the inbreeding coefficients
(so called F I, F II and F III) after Yang et al. for all
samples [22]. The means (SDs) for F I in cases and
controls were 0.003 (0.01) and -0.0005 (0.006), re-
spectively, and significantly different from each other
(P = 2.94 × 10−13, by Student’s t-test). Thus, there was
significant evidence that cases were more inbred
than controls. This was supported by the inbreeding
coefficient F III, which also differed significantly
between cases and controls at P = 3.77 × 10−6 with
Table 4 P-values for differences of inbreeding coefficients F I, F
II and F III between cases and controls
CHR. Length in BP F I* F II* F III*
1 239482994 0.16 0.39 0.22
2 237975642 0.006 0.01 0.01
3 195481660 0.19 0.28 0.11
4 187415093 0.0002 0.01 0.008
5 175834594 4.52 × 10−5 0.03 0.0009
6 165666786 0.09 0.50 0.64
7 154972229 0.01 0.72 0.36
8 141209234 0.0004 0.69 0.04
9 126549725 0.12 0.22 0.17
10 131868223 0.02 0.54 0.11
11 129246417 0.27 0.60 0.71
12 128925838 0.01 0.30 0.07
13 91046560 0.01 0.15 0.15
14 82460885 0.44 0.80 0.82
15 77621221 0.07 0.74 0.12
16 82341226 0.26 0.66 0.68
17 77544622 0.02 0.55 0.41
18 74113617 0.23 0.57 0.78
19 60064206 0.02 0.13 0.04
20 59665714 0.002 0.47 0.09
21 30132781 0.001 0.89 0.15
22 27989019 0.63 0.63 0.67
*bold values show significant differences between cases and controls
at P < 0.05
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cases being more inbred. The inbreeding coefficient
F II was in cases 0.002 (0.01) and in controls 0.001
(0.007), but differences were not significant. Table 4
lists the P values for the test of true differences of F I, F II
and F III between cases and controls separately for each
chromosome. Chromosomes 2, 4, 5 and 8 were signifi-
cantly different. For all chromosomes cases showed higher
values for F I, F II and F III than controls.
When using a GLM with several covariates and regres-
sing the explanatory variables F I, F II or F III on the
disease status of the TC patient as the binary response
(0/1), F I and F III remained significant at P = 0.003 with
a positive effect estimate of 32.19 and 64.38, respectively.
This results in an increasing slope of the regression line
towards the diseased individuals. F II was also significant
at P = 0.01.
A more detailed overview on the characteristics of the
inbreeding coefficient for cases and controls is demon-
strated in Fig. 1, which shows the variation of the in-
breeding coefficient between chromosomes. The mean is
rather constant across the chromosomes but the vari-
ation is increasing from chromosome 1 to 22 while the
length of the chromosomes in base pairs is decreasing
(r = −0.80, P = 6.51 × 10−6).
Three additional associations for different consan-
guinity measures were tested (Fig. 2). The total
length of individual ROHs was highly correlated
with the total number of ROHs per individual (r = 0.77,
Fig. 1 Variation of inbreeding coefficients among chromosomes for cases (a) and controls (b). The boxplot figure shows the means and variation
of the inbreeding coefficient F I for autosomal chromosomes 1 to 22 for cases (red) and controls (green)
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Fig. 2 (See legend on next page.)
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P < 2.20 × 10−16). A significant association was also de-
termined for the total length of ROHs per individual
and the individual inbreeding coefficient F III (r = 0.83,
P < 2.20 × 10−16) and for the total number of ROHs per
individual and the individual inbreeding coefficient F III
(r = 0.55, P < 2.20 × 10−16).
Finally, FROH was also 0.22 units of standard deviation
SD (P = 1.95 × 10−5) higher in cases than controls. The cor-
relation between the inbreeding coefficients and FROH were
also highly significant (F I: r = 0.71, P = 2.20 × 10−16; F II:
r = 0.72, P = 2.20 × 10−16; F III: r = 0.83, P = 2.20 × 10−16).
Discussion
Based on our previous GWAS we showed here that the
proportion of the total phenotypic variance in TC risk
explained by all common SNPs is about 0.51. After cor-
recting for identified TC risk loci about two-thirds of
the genetic variance remain to be identified [11, 17].
This fact clearly shows the high influence of both the
genetic factors and the environment on the susceptibility
of TC. In the present study, we sought to find other gen-
etic explanations than genes identified through previous
GWASs that function in a co-dominant manner. The
focus was shifted towards recessive inheritance. The
current work is to our knowledge the first analysis of the
influence of genomic homozygosity and genomic in-
breeding on the susceptibility to TC.
Already the genome-wide SNP-by-SNP analysis showed
significantly higher proportion of homozygous genotypes
among the cases than controls. Further downstream ana-
lyses revealed significant differences between cases and
controls in terms of the number and length of ROHs per
person.
It is known that homozygosity can be caused by demo-
graphic events, consanguinity/inbreeding or selective
pressure [33, 34]. Most of the ROHs in our study were
rather short though. This excludes recent consanguinity
as the cause of inbreeding. However, the significant gen-
omic inbreeding coefficients point to a certain level of
relatedness that might remain from distant consanguin-
ity. All the ROHs of interest showed significant evidence
for natural selection (iHS, Fst, Fay and Wu’s H) [28]. The
influence of selective pressure on the ROH length can
therefore not be excluded.
The analysis of specific overlapping ROHs did not re-
sult in a genome-wide significance, however, several
ROHs were matching with regions that contain genes
related to TC susceptibility. The majority of overlapping
ROHs was absent in controls. Homozygosity in these
ROHs might have been disappeared over time due to re-
combination. Only for ROH1, ROH3, ROH4 and ROH5
we detected more controls than cases to be homozygous
for an overlapping ROH region. One of these, ROH5
overlaps with long contiguous stretches of homozygosity
from other studies [35, 36]. However, in 10 out of 16
consensus regions significantly higher amount of homo-
zygous SNPs were observed among cases than among
controls. Thus, the inheritance of recessive genes har-
bored in these regions might be possible.
Our study shows some evidence of an association be-
tween extended stretches of homozygosity and an in-
creased TC risk. This result is not unexpected as several
studies before have detected association between ROHs
and cancer susceptibility [16].
The novel result of our study is the significant effect of
genomic inbreeding among cases and its relevant effect
on the development of the disease. The inbreeding coef-
ficients F I, F II, and F III were significantly higher in
cases than in controls, even after correcting for numer-
ous covariates using GLM. Inbreeding is supposed to
reduce fitness by causing an overabundance of homozy-
gous loci and increasing the probability of deleterious
rare alleles that lead to inbreeding depression [37]. As
inbreeding is related to homozygosity, the chances of
offspring being affected by recessive or deleterious traits
are therefore increased [38]. In fact, the assumption that
a higher level of inbreeding or increased homozygosity
correlates with cancer incidence has been proven already
before on the genomic level [16].
Even the results of the FROH support the higher in-
breeding among cases compared with controls, although
FROH is discarding SNPs in regions outside of ROHs that
are below our stringent length criterion. The fact, that
we found no significant differences among cases and
controls in the mean sum of shorter ROHs but highly
significant differences for the longer ROHs supports the
view that the differences in ROH length longer than
20 Mb reflect effects of more recent consanguinity ra-
ther than LD pattern of ancient origin. It has been
shown that consanguinity increased in Italy early in the
20th century and subsequently decreased. This has been
explained by population growth in the early 20th century
and changing demographics since then [39]. Another
reason is the very large number of distantly related
(See figure on previous page.)
Fig. 2 Pearson's correlation coefficients for different consanguinity measures. The total length of individual ROHs is highly correlated with the
total number of ROHs per individual (r = 0.77, P < 2.20*10-16) (a). A high association is determined for the total length of ROHs in Mb and the
individual inbreeding coefficient F III (r = 0.83, P < 2.20*10-16) (b), while the lowest association was determined for the total number of ROHs per
individual and the individual inbreeding coefficient F III (r = 0.55, P < 2.20*10-16) (c)
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spouses in determining the population level of inbreed-
ing [39]. With this source of a consanguineous popula-
tion we had the unique opportunity to detect recessively
inherited genomic regions for TC.
Conclusion
We showed evidence for long ROHs to increase the risk
of TC. Higher inbreeding among cases supports the exist-
ence of recessive alleles affecting TC risk. The genetic
architecture of TC is highly supported by a genetic model,
in which the variants of a complex disease are more likely
to be rare than common. They are also likely to be numer-
ous with highly polygenic architecture and of a small indi-
vidual effect at the population level. If this view of the
genetic architecture of common complex diseases is cor-
rect, then it would be important to consider inbreeding as
a factor having an influence on the disease.
Supplementary information is available at the journals
website.
Additional file
Additional file 1: Figure S1. Example for recurrent ROHs in the
telomeric region of chromosome 15 for 6 cases. (PDF 335 kb)
Abbreviations
BP: base pair; CEU: Utah residents with ancestry from northern and western
Europe; CHR: chromosome; CI: confidence interval; F: inbreeding coefficient;
FDR: false discovery rate; Fst: Fixation index; GCTA: genome-wide complex
trait analysis; GLM: generalized linear regression model; GRM: genetic
relationship matrix; GWAS: Genome-wide association study; iHS: integrated
haplotype score; kb: Kilo-base pair; LD: linkage disequilibrium; Mb: Mega base
pair; MLM: mixed linear model; OR: odds ratio; PTC: papillary thyroid cancer;
REML: restricted maximum likelihood; ROH: runs of homozygosity;
SD: standard deviation; SE: standard error; SNP: single-nucleotide
polymorphism; TC: thyroid cancer.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
HT, AF, FG, KH, SL organized and designed the study. BC, GF, PH and SH
performed the GWAS RE, CR, MC, AC and FB were responsible of the
collection of samples. HT performed the statistical analysis. HT, AF, KH wrote
and reviewed the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
The Italian part of the study has received financial support from the Istituto
Toscano Tumori.
Author details
1Molecular Genetic Epidemiology, C050, German Cancer Research Center
(DKFZ), Im Neuenheimer Feld 580, 69120 Heidelberg, Germany. 2Department
of Biology, University of Pisa, Pisa, Italy. 3Department of Endocrinology and
Metabolism, University of Pisa, Pisa, Italy. 4Blood Centre, Azienda Ospedaliero
Universitaria A. Meyer, Firenze, Italy. 5Department of Genomics, Life and Brain
Center, University of Bonn, Bonn, Germany. 6Division of Medical Genetics,
University Hospital Basel, Basel, Switzerland. 7Department of Biomedicine,
University Hospital Basel, Basel, Switzerland. 8Center for Primary Health Care
Research, Clinical Research Center, Lund University, Malmö, Sweden.
Received: 11 September 2015 Accepted: 9 March 2016
References
1. Agate L, Lorusso L, Elisei R. New and old knowledge on differentiated
thyroid cancer epidemiology and risk factors. J Endocrinol Investig.
2012;35(6 Suppl):3–9.
2. Li N, Du XL, Reitzel LR, Xu L, Sturgis EM. Impact of enhanced detection on the
increase in thyroid cancer incidence in the United States: review of incidence
trends by socioeconomic status within the surveillance, epidemiology, and
end results registry, 1980-2008. Thyroid. 2013;23(1):103–10.
3. Tehranifar P, Wu HC, Shriver T, Cloud AJ, Terry MB. Validation of family cancer
history data in high-risk families: the influence of cancer site, ethnicity, kinship
degree, and multiple family reporters. Am J Epidemiol. 2015;181(3):204–12.
4. Cardis E, Kesminiene A, Ivanov V, Malakhova I, Shibata Y, Khrouch V,
Drozdovitch V, Maceika E, Zvonova I, Vlassov O, et al. Risk of thyroid cancer
after exposure to 131I in childhood. J Natl Cancer Inst. 2005;97(10):724–32.
5. Hemminki K, Eng C, Chen B. Familial risks for nonmedullary thyroid cancer.
J Clin Endocrinol Metab. 2005;90(10):5747–53.
6. Hemminki K, Sundquist J, Lorenzo Bermejo J. Familial risks for cancer as the
basis for evidence-based clinical referral and counseling. Oncologist.
2008;13(3):239–47.
7. Bonora E, Tallini G, Romeo G. Genetic predisposition to familial
nonmedullary thyroid cancer: An update of molecular findings and state-of-
the-art studies. Journal of oncology. 2010;2010:385206.
8. Gudmundsson J, Sulem P, Gudbjartsson DF, Jonasson JG, Masson G, He H,
Jonasdottir A, Sigurdsson A, Stacey SN, Johannsdottir H, et al. Discovery of
common variants associated with low TSH levels and thyroid cancer risk.
Nat Genet. 2012;44(3):319–22.
9. Gudmundsson J, Sulem P, Gudbjartsson DF, Jonasson JG, Sigurdsson A,
Bergthorsson JT, He H, Blondal T, Geller F, Jakobsdottir M, et al. Common
variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European
populations. Nat Genet. 2009;41(4):460–4.
10. Takahashi M, Saenko VA, Rogounovitch TI, Kawaguchi T, Drozd VM, Takigawa-
Imamura H, Akulevich NM, Ratanajaraya C, Mitsutake N, Takamura N, et al. The
FOXE1 locus is a major genetic determinant for radiation-related thyroid
carcinoma in Chernobyl. Hum Mol Genet. 2010;19(12):2516–23.
11. Kohler A, Chen B, Gemignani F, Elisei R, Romei C, Figlioli G, Cipollini M,
Cristaudo A, Bambi F, Hoffmann P, et al. Genome-wide association study on
differentiated thyroid cancer. J Clin Endocrinol Metab. 2013;98(10):E1674–1681.
12. Bener A, El Ayoubi HR, Chouchane L, Ali AI, Al-Kubaisi A, Al-Sulaiti H, Teebi
AS. Impact of consanguinity on cancer in a highly endogamous population.
Asian Pac J Cancer Prev. 2009;10(1):35–40.
13. Kijas JW. Detecting regions of homozygosity to map the cause of
recessively inherited disease. Methods Mol Biol. 2013;1019:331–45.
14. Spain SL, Cazier JB, Consortium C, Houlston R, Carvajal-Carmona L, Tomlinson I.
Colorectal cancer risk is not associated with increased levels of homozygosity
in a population from the United Kingdom. Cancer Res. 2009;69(18):7422–9.
15. Enciso-Mora V, Hosking FJ, Houlston RS. Risk of breast and prostate cancer
is not associated with increased homozygosity in outbred populations. Eur J
Hum Genet. 2010;18(8):909–14.
16. Wang C, Xu Z, Jin G, Hu Z, Dai J, Ma H, Jiang Y, Hu L, Chu M, Cao S, et al.
Genome-wide analysis of runs of homozygosity identifies new susceptibility
regions of lung cancer in Han Chinese. Journal of biomedical research.
2013;27(3):208–14.
17. Figlioli G, Kohler A, Chen B, Elisei R, Romei C, Cipollini M, Cristaudo A, Bambi
F, Paolicchi E, Hoffmann P, et al. Novel genome-wide association study-
based candidate loci for differentiated thyroid cancer risk. J Clin Endocrinol
Metab. 2014;99(10):E2084–2092.
18. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J,
Sklar P, de Bakker PI, Daly MJ, et al. PLINK: a tool set for whole-genome
association and population-based linkage analyses. Am J Hum Genet. 2007;
81(3):559–75.
19. Anderson CA, Pettersson FH, Clarke GM, Cardon LR, Morris AP, Zondervan
KT. Data quality control in genetic case-control association studies. Nat
Protoc. 2010;5(9):1564–73.
20. Yang J, Benyamin B, McEvoy BP, Gordon S, Henders AK, Nyholt DR, Madden PA,
Heath AC, Martin NG, Montgomery GW, et al. Common SNPs explain a large
proportion of the heritability for human height. Nat Genet. 2010;42(7):565–9.
21. Dempster ER, Lerner IM. Heritability of threshold characters. Genetics.
1950;35(2):212–36.
Thomsen et al. BMC Cancer  (2016) 16:227 Page 10 of 11
22. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide
complex trait analysis. Am J Hum Genet. 2011;88(1):76–82.
23. Weller JI, Song JZ, Heyen DW, Lewin HA, Ron M. A new approach to the
problem of multiple comparisons in the genetic dissection of complex
traits. Genetics. 1998;150(4):1699–706.
24. Howrigan DP, Simonson MA, Keller MC. Detecting autozygosity through
runs of homozygosity: a comparison of three autozygosity detection
algorithms. BMC Genomics. 2011;12:460.
25. Team RC. R: A language and environment for statistical computing. 2013.
26. Lencz T, Lambert C, DeRosse P, Burdick KE, Morgan TV, Kane JM, Kucherlapati
R, Malhotra AK. Runs of homozygosity reveal highly penetrant recessive loci in
schizophrenia. Proc Natl Acad Sci U S A. 2007;104(50):19942–7.
27. Pemberton TJ, Absher D, Feldman MW, Myers RM, Rosenberg NA, Li JZ.
Genomic patterns of homozygosity in worldwide human populations. Am J
Hum Genet. 2012;91(2):275–92.
28. Voight BF, Kudaravalli S, Wen X, Pritchard JK. A map of recent positive
selection in the human genome. PLoS Biol. 2006;4(3):e72.
29. Fay JC, Wu CI. Hitchhiking under positive Darwinian selection. Genetics.
2000;155(3):1405–13.
30. McQuillan R, Leutenegger AL, Abdel-Rahman R, Franklin CS, Pericic M,
Barac-Lauc L, Smolej-Narancic N, Janicijevic B, Polasek O, Tenesa A, et al.
Runs of homozygosity in European populations. Am J Hum Genet. 2008;
83(3):359–72.
31. Coop G, Pickrell JK, Novembre J, Kudaravalli S, Li J, Absher D, Myers RM,
Cavalli-Sforza LL, Feldman MW, Pritchard JK. The role of geography in
human adaptation. PLoS Genet. 2009;5(6):e1000500.
32. Oleksyk TK, Smith MW, O’Brien SJ. Genome-wide scans for footprints of natural
selection. Philos Trans R Soc Lond Ser B Biol Sci. 2010;365(1537):185–205.
33. Siraj AK, Khalak HG, Sultana M, Al-Rasheed M, Bavi P, Al-Sanea N, Al-Dayel F,
Uddin S, Alkuraya FS, Al-Kuraya KS. Colorectal cancer risk is not associated
with increased levels of homozygosity in Saudi Arabia. Genet Med. 2012;
14(8):720–28.
34. Woods CG, Cox J, Springell K, Hampshire DJ, Mohamed MD, McKibbin M,
Stern R, Raymond FL, Sandford R, Malik Sharif S, et al. Quantification of
homozygosity in consanguineous individuals with autosomal recessive
disease. Am J Hum Genet. 2006;78(5):889–96.
35. Li LH, Ho SF, Chen CH, Wei CY, Wong WC, Li LY, Hung SI, Chung WH, Pan
WH, Lee MT, et al. Long contiguous stretches of homozygosity in the
human genome. Hum Mutat. 2006;27(11):1115–21.
36. Gibson J, Morton NE, Collins A. Extended tracts of homozygosity in outbred
human populations. Hum Mol Genet. 2006;15(5):789–95.
37. Spielman D, Brook BW, Briscoe DA, Frankham R. Does inbreeding and loss of
genetic diversity decrease disease resistance? Conserv Genet. 2004;5(4):439–48.
38. Nabulsi MM, Tamim H, Sabbagh M, Obeid MY, Yunis KA, Bitar FF. Parental
consanguinity and congenital heart malformations in a developing country.
Am J Med Genet A. 2003;116A(4):342–7.
39. Cavalli-Sforza LL, Moroni A, Zei G. Consanguinity, inbreeding, and genetic
drift in Italy (MPB-39). Princeton: University Press; 2013.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Thomsen et al. BMC Cancer  (2016) 16:227 Page 11 of 11
